Alder BioPharmaceuticals (ALDR) Stock Price Up 17.4% After Analyst Upgrade

Shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) rose 17.4% during mid-day trading on Tuesday after BMO Capital Markets raised their price target on the stock to $26.00. BMO Capital Markets currently has an outperform rating on the stock. Alder BioPharmaceuticals traded as high as $16.00 and last traded at $15.20. Approximately 6,900,700 shares changed hands during mid-day trading, an increase of 195% from the average daily volume of 2,342,060 shares. The stock had previously closed at $12.95.

A number of other analysts have also recently issued reports on ALDR. Royal Bank of Canada initiated coverage on shares of Alder BioPharmaceuticals in a research note on Thursday, September 14th. They issued an “outperform” rating and a $17.00 target price for the company. Mizuho reiterated a “buy” rating and issued a $32.00 target price on shares of Alder BioPharmaceuticals in a research note on Friday, September 15th. Cowen initiated coverage on shares of Alder BioPharmaceuticals in a research note on Tuesday, September 26th. They issued an “outperform” rating and a $20.00 target price for the company. ValuEngine raised shares of Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 30th. Finally, Canaccord Genuity initiated coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, October 26th. They issued a “buy” rating and a $20.00 price target on the stock. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $27.79.

In related news, insider Mark James Litton sold 16,519 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $10.80, for a total transaction of $178,405.20. Following the transaction, the insider now owns 116,451 shares of the company’s stock, valued at $1,257,670.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 10.60% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc increased its holdings in Alder BioPharmaceuticals by 2.6% in the 2nd quarter. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company’s stock valued at $177,000 after buying an additional 400 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Alder BioPharmaceuticals by 1.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,488 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 698 shares during the period. Voya Investment Management LLC increased its holdings in Alder BioPharmaceuticals by 8.4% in the 2nd quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,734 shares during the period. Russell Investments Group Ltd. increased its holdings in Alder BioPharmaceuticals by 7.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 42,416 shares of the biopharmaceutical company’s stock valued at $486,000 after buying an additional 2,837 shares during the period. Finally, Teachers Advisors LLC increased its holdings in Alder BioPharmaceuticals by 3.8% in the 2nd quarter. Teachers Advisors LLC now owns 84,705 shares of the biopharmaceutical company’s stock valued at $970,000 after buying an additional 3,091 shares during the period. 96.80% of the stock is currently owned by institutional investors and hedge funds.

The stock has a market cap of $1,190.00, a price-to-earnings ratio of -3.27 and a beta of 2.48.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.21) by $0.29. During the same quarter in the prior year, the business posted ($0.70) earnings per share. research analysts predict that Alder BioPharmaceuticals, Inc. will post -5.14 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Alder BioPharmaceuticals (ALDR) Stock Price Up 17.4% After Analyst Upgrade” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/10/alder-biopharmaceuticals-aldr-stock-price-up-17-4-after-analyst-upgrade.html.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply